BioCentury
ARTICLE | Clinical News

DCR-MYC: Interim Phase I data

June 1, 2015 7:00 AM UTC

Interim data from 19 patients with solid tumors, multiple myeloma or lymphoma in an open-label, dose-escalation, U.S. Phase I trial showed that 0.1-0.3 mg/kg IV DCR-MYC on days 1 and 8 of each 21-day ...